Provided by Tiger Trade Technology Pte. Ltd.

Supernus Pharmaceuticals

45.85
-1.6000-3.37%
Post-market: 45.850.00000.00%19:30 EDT
Volume:748.89K
Turnover:34.79M
Market Cap:2.66B
PE:-23.95
High:47.82
Open:47.71
Low:45.79
Close:47.45
52wk High:59.68
52wk Low:42.45
Shares:58.04M
Float Shares:51.67M
Volume Ratio:1.29
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9145
EPS(LYR):-0.6829
ROE:-10.49%
ROA:0.39%
PB:2.58
PE(LYR):-67.14

Loading ...

Supernus Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

U.S. Stocks on the MOVE -Visa, Bowhead Specialty, Micron

Reuters
·
Aug 03

UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate

Benzinga Earnings
·
Aug 03

Supernus, Indivior Merge to Strengthen Neuroscience Drug Portfolio

Reuters
·
Aug 03

Supernus Pharmaceuticals Swings to Q2 Net Loss, Revenue Rises; Fiscal 2026 Revenue Outlook Raised

MT Newswires Live
·
Aug 03

Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger

MT Newswires Live
·
Aug 03

Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, vs. FactSet Est of $0.04 EPS

MT Newswires Live
·
Aug 03

Supernus Pharmaceuticals Q2 EPS USD -1.01

Reuters
·
Aug 03

Supernus Q2 FY26 Net Loss Widens to $58.4 Million; Revenue Rises 32% to $219.1 Million

Reuters
·
Aug 03

Supernus Pharmaceuticals Shares Rise 5.3% Premarket After Co to Merge with Indivior Pharmaceuticals

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Q2 Product Sales USD 165.7 Million

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Outlook FY Revenue USD 860-890 Million

THOMSON REUTERS
·
Aug 03

Supernus Announces Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 03

Supernus, Indivior Agree All-Stock Merger, Combined Firm to Trade as Supernus on NASDAQ

Reuters
·
Aug 03

Supernus Pharmaceuticals - Stockholders Will GET 1.5401 Common Shares of Indivior Pharmaceuticals for Each Share of Supernus Pharmaceuticals They Own

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc: Indivior Pharmaceuticals Stockholders Will Own Approximately 56.5% of Combined Company

THOMSON REUTERS
·
Aug 03

Supernus: Combined Co Expected to Benefit from Immediate Scale and $125 Mln of Expected Annual Cost Synergies

THOMSON REUTERS
·
Aug 03

Supernus: Indivior Pharmaceuticals Stockholders to GET One-Time Special Cash Dividend of $1 Bln in Aggregate Immediately Prior to Closing of Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Definitive Agreement to Combine in a Tax-Free All-Stock Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Combined Entity to be Named Supernus, Inc. and Jack Khattar to Serve as President and Chief Executive Officer

THOMSON REUTERS
·
Aug 03